In the Lab
Potential Drug Shows Promise Targeting a Range of KRAS-Driven Cancers in the Lab
MSK investigators report exciting results for a new molecule that can block 16 different mutated forms of the KRAS protein. In the lab, the compound was effective against many cancer cell lines and in mouse models of lung cancer and colorectal cancer.
Finding
MSK Researchers Are Learning Why Some Patients Develop Resistance to Targeted Lung Cancer Drug
A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.
In the Lab
Researchers Uncover New Findings about KRAS, an Important Protein in Cancer
Researchers have taken a closer look at what a protein called KRAS does in normal cells and how certain KRAS mutations lead to for cancer growth.
Feature
How Four Decades of Research Led to an Important Advance in Lung Cancer
Read how a clinical trial is changing the outlook for some people with lung cancer.
In the Clinic
Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS
The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.
In the Lab
Why KRAS Inhibitors for Lung Cancer Stop Working (and What Can Be Done about It)
Recently developed targeted drugs used to treat lung cancer are only partially effective. Scientists now know why.
In the Lab
Giving Drugs Together — Rather than in Sequence — May Be Key to Halting Tumor Resistance
Scientists are learning how tumors develop resistance to drugs — and what can be done about it.
In the Lab
New Lung Cancer Therapy May Target Previously Untreatable Tumors
Researchers are developing uses for a drug that could benefit many people with lung cancer.
